Redeye recognizes the Aprea Therapeutics (Aprea) phase 3 top-line results as a miss and disappointing. Even though the top-line result is not a clear miss and will entail further analysis on the full dataset, the some -80% stock reaction in Aprea has a major impact on Karolinska Development (KD). We update our Fair Values with immediate effect.